Business Context and Reporting Period
This Form 8-K was filed by Sana Biotechnology, Inc. on April 22, 2026. The report addresses a corporate governance action regarding the Board of Directors to ensure compliance with the Company's Amended and Restated Certificate of Incorporation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific event and does not contain financial statements.
Material Changes
The Board reclassified one director to achieve an equal balance of three directors in each of the three Board classes (Class I, II, and III). Specifically, Steven D. Harr, M.D., resigned as a Class I director (term expiring 2028) and was immediately re-appointed as a Class III director (term expiring 2027). This action was taken solely for rebalancing purposes, and Dr. Harr's service is deemed uninterrupted.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the procedural details of the director reclassification.
Key Facts for Investor Verification
- Steven D. Harr, M.D., remains on the Board but his term expiration date has shifted from the 2028 annual meeting to the 2027 annual meeting.
- The Board composition is now balanced with three directors in each of the three classes.
- The reclassification was executed to comply with the Company's Certificate of Incorporation.